ASCO 2013 Report — Malignant Hematology

Highlights of new strategies and treatments for patients with diffuse large B-cell lymphoma, Hodgkin lymphoma, multiple myeloma, and chronic lymphocytic leukemia

At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2013), held May 31 through June 5 in Chicago, specialists discussed the latest cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to cover key presentations at the conference. Here, Michael E. Williams, MD, reviews new findings in malignant hematology.

Routine Surveillance Imaging Provides Minimal Benefit in Lymphoma

Retrospective studies have shown that lymphoma patients in first complete remission (CR) gain no survival advantage from routine surveillance imaging (RSI). Given these results, as well as the cumulative radiation exposure and costs associated with RSI, Thompson and colleagues prospectively assessed the value of R…

Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee